Imunon (IMNN) Competitors $5.09 +0.03 (+0.59%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$5.08 0.00 (-0.10%) As of 10/17/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNN vs. IPSC, ADAP, VNRX, ESLA, KPTI, LTRN, MRSN, TPST, NBRV, and RVPHShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Century Therapeutics (IPSC), Adaptimmune Therapeutics (ADAP), VolitionRx (VNRX), Estrella Immunopharma (ESLA), Karyopharm Therapeutics (KPTI), Lantern Pharma (LTRN), Mersana Therapeutics (MRSN), Tempest Therapeutics (TPST), Nabriva Therapeutics (NBRV), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. Imunon vs. Its Competitors Century Therapeutics Adaptimmune Therapeutics VolitionRx Estrella Immunopharma Karyopharm Therapeutics Lantern Pharma Mersana Therapeutics Tempest Therapeutics Nabriva Therapeutics Reviva Pharmaceuticals Imunon (NASDAQ:IMNN) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations. Which has more risk & volatility, IMNN or IPSC? Imunon has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Does the media prefer IMNN or IPSC? In the previous week, Century Therapeutics had 1 more articles in the media than Imunon. MarketBeat recorded 4 mentions for Century Therapeutics and 3 mentions for Imunon. Century Therapeutics' average media sentiment score of 0.19 beat Imunon's score of -0.33 indicating that Century Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is IMNN or IPSC more profitable? Imunon has a net margin of 0.00% compared to Century Therapeutics' net margin of -19.10%. Century Therapeutics' return on equity of -11.53% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -405.07% -158.41% Century Therapeutics -19.10%-11.53%-6.94% Do institutionals & insiders believe in IMNN or IPSC? 4.5% of Imunon shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 6.0% of Imunon shares are owned by insiders. Comparatively, 5.0% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has better earnings & valuation, IMNN or IPSC? Imunon has higher earnings, but lower revenue than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunonN/AN/A-$18.62M-$12.95-0.39Century Therapeutics$114.13M0.41-$126.57M-$0.29-1.87 Do analysts prefer IMNN or IPSC? Imunon presently has a consensus price target of $232.50, indicating a potential upside of 4,467.78%. Century Therapeutics has a consensus price target of $3.75, indicating a potential upside of 591.50%. Given Imunon's higher possible upside, analysts plainly believe Imunon is more favorable than Century Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Century Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryCentury Therapeutics beats Imunon on 9 of the 15 factors compared between the two stocks. Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.35M$3.39B$6.09B$10.49BDividend YieldN/A2.28%5.73%4.80%P/E Ratio-0.3923.1685.6227.13Price / SalesN/A267.66517.46179.23Price / CashN/A47.1837.2361.22Price / Book1.3310.4112.236.52Net Income-$18.62M-$52.77M$3.33B$276.93M7 Day Performance0.59%2.31%1.17%1.93%1 Month Performance-0.20%11.13%6.14%2.19%1 Year Performance-65.57%11.12%59.98%34.99% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon1.4807 of 5 stars$5.09+0.6%$232.50+4,467.8%-65.3%$12.42M$500K0.0030Short Interest ↑IPSCCentury Therapeutics2.7461 of 5 stars$0.55-3.3%$3.75+581.9%-65.5%$49.13M$6.59M-1.90170ADAPAdaptimmune Therapeutics1.9391 of 5 stars$0.18-2.6%$1.35+650.5%-76.2%$49.01M$178.03M-0.28490Gap DownVNRXVolitionRx2.7716 of 5 stars$0.45-2.5%$3.50+673.1%-39.1%$48.71M$1.32M-1.2680News CoverageGap UpHigh Trading VolumeESLAEstrella Immunopharma2.869 of 5 stars$1.50+16.3%$16.00+966.7%+108.3%$47.81MN/A-5.77N/APositive NewsShort Interest ↓Gap DownHigh Trading VolumeKPTIKaryopharm Therapeutics4.2048 of 5 stars$5.62+2.2%$18.20+223.8%-53.7%$47.69M$145.24M-0.39380Analyst RevisionLTRNLantern Pharma1.7533 of 5 stars$4.41+1.6%$25.00+466.9%+17.1%$46.87MN/A-2.4820News CoverageGap UpMRSNMersana Therapeutics4.0986 of 5 stars$9.91+7.3%$56.60+471.1%-81.3%$46.11M$40.50M-0.68150High Trading VolumeTPSTTempest Therapeutics1.432 of 5 stars$11.53+12.3%$30.00+160.2%-32.2%$45.60MN/A-0.7920NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RVPHReviva Pharmaceuticals3.0378 of 5 stars$0.63-3.8%$4.86+676.5%-55.1%$45.06MN/A-0.965Gap Down Related Companies and Tools Related Companies IPSC Competitors ADAP Competitors VNRX Competitors ESLA Competitors KPTI Competitors LTRN Competitors MRSN Competitors TPST Competitors NBRV Competitors RVPH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNN) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThis dark force is about to change everythingSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredElon’s Optimus to mint new “Musk Millionaires” as soon as Oct 23???Elon Musk may be set to create more "Musk Millionaires" as soon as October 23rd… Because on that day, he's exp...InvestorPlace | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNN Stock Alerts